Neurology and Research Services, New Mexico VA Healthcare System, Albuquerque, NM 87108;
Department of Neurology, University of New Mexico, Albuquerque, NM 87131.
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11597-11602. doi: 10.1073/pnas.1720446115. Epub 2018 Oct 22.
Receptor-type protein tyrosine phosphatase D (PTPRD) is a neuronal cell-adhesion molecule/synaptic specifier that has been implicated in addiction vulnerability and stimulant reward by human genomewide association and mouse cocaine-conditioned place-preference data. However, there have been no reports of effects of reduced expression on cocaine self-administration. There have been no reports of PTPRD targeting by any small molecule. There are no data about behavioral effects of any PTPRD ligand. We now report () robust effects of heterozygous PTPRD KO on cocaine self-administration (These data substantially extend prior conditioned place-preference data and add to the rationale for PTPRD as a target for addiction therapeutics.); () identification of 7-butoxy illudalic acid analog (7-BIA) as a small molecule that targets PTPRD and inhibits its phosphatase with some specificity; () lack of toxicity when 7-BIA is administered to mice acutely or with repeated dosing; () reduced cocaine-conditioned place preference when 7-BIA is administered before conditioning sessions; and () reductions in well-established cocaine self-administration when 7-BIA is administered before a session (in WT, not PTPRD heterozygous KOs). These results add to support for PTPRD as a target for medications to combat cocaine use disorders. 7-BIA provides a lead compound for addiction therapeutics.
受体型蛋白酪氨酸磷酸酶 D(PTPRD)是一种神经元细胞黏附分子/突触特化因子,通过人类全基因组关联和小鼠可卡因条件性位置偏好数据,它与成瘾易感性和兴奋剂奖励有关。然而,目前尚无关于降低表达对可卡因自我给药影响的报道。也没有关于任何小分子靶向 PTPRD 的报道。没有关于任何 PTPRD 配体的行为效应的数据。我们现在报告()杂合 PTPRD KO 对可卡因自我给药的显著影响(这些数据大大扩展了先前的条件性位置偏好数据,并为 PTPRD 作为成瘾治疗靶点增加了依据);()鉴定出 7-丁氧基伊鲁达酸类似物(7-BIA)作为一种靶向 PTPRD 的小分子,并具有一定特异性抑制其磷酸酶;()7-BIA 急性或重复给药时无毒性;()在条件作用前给予 7-BIA 可降低可卡因条件性位置偏好;()在一次治疗前给予 7-BIA 可降低可卡因自我给药(在 WT 中,而非 PTPRD 杂合 KO)。这些结果进一步支持 PTPRD 作为治疗可卡因使用障碍的药物靶点。7-BIA 为成瘾治疗提供了一种先导化合物。